Holt Capital Advisors, L.L.C. Dba Holt Capital Partners, L.P. Vertex Pharmaceuticals Inc Transaction History
Holt Capital Advisors, L.L.C. Dba Holt Capital Partners, L.P.
- $654 Million
- Q4 2024
A detailed history of Holt Capital Advisors, L.L.C. Dba Holt Capital Partners, L.P. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Holt Capital Advisors, L.L.C. Dba Holt Capital Partners, L.P. holds 1,968 shares of VRTX stock, worth $952,984. This represents 0.12% of its overall portfolio holdings.
Number of Shares
1,968
Previous 1,973
0.25%
Holding current value
$952,984
Previous $917,000
13.63%
% of portfolio
0.12%
Previous 0.14%
Shares
6 transactions
Others Institutions Holding VRTX
# of Institutions
1,753Shares Held
227MCall Options Held
1.63MPut Options Held
1.47M-
Capital World Investors Los Angeles, CA28.3MShares$13.7 Billion1.8% of portfolio
-
Vanguard Group Inc Valley Forge, PA23.3MShares$11.3 Billion0.17% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$10.3 Billion0.23% of portfolio
-
State Street Corp Boston, MA12MShares$5.8 Billion0.2% of portfolio
-
Capital Research Global Investors Los Angeles, CA10.4MShares$5.05 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $124B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...